Immutrin
PrivateLast Round
Series A
Mar 24, 2026
Total Funding Raised
$87M
Company Overview
Immutrin is a biotechnology company that develops antibody therapies intended to treat systemic and local amyloidosis by removing harmful amyloid deposits.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immutrin Comps
Public and private peers based on sector, stage, and business model.
Immutrin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 |
Immutrin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Frazier Life Sciences | Series A |
| Cambridge Innovation Capital | Series A |
| F-Prime Capital | Series A |
| Qiming Venture Partners | Series A |
| SR One | Series A |
| University of Cambridge Venture Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2026
Raised $87M in Series A funding.
Immutrin Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immutrin's valuation, stock price, and market status.
